SCHEMBL6906446

SCHEMBL6906446

O=C1C(=Cc2ccccc2)SC(=S)N1NS(=O)(=O)c1ccccc1

nearest known ligand 0.86

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 13/20 0.86
▸ MEN1 O00255 11/20 0.86
▸ CRHBP P24387 3/20 0.86
▸ CRHR2 Q13324 3/20 0.86
▸ MAPT P10636 6/20 0.74
▸ POLB P06746 3/20 0.73
▸ NSD2 O96028 1/20 0.71
▸ PLA2G1B P04054 1/20 0.71
▸ CASP3 P42574 1/20 0.71
▸ MCL1 Q07820 1/20 0.71
▸ SENP8 Q96LD8 1/20 0.71
▸ SENP7 Q9BQF6 1/20 0.71
▸ SENP6 Q9GZR1 1/20 0.71
▸ ATG4B Q9Y4P1 1/20 0.71
▸ SMN1; SMN2 Q16637 1/20 0.71
▸ NPSR1 Q6W5P4 1/20 0.71
▸ L3MBTL1 Q9Y468 1/20 0.71
▸ MAPK1 P28482 1/20 0.67
▸ RECQL P46063 1/20 0.67
▸ GFER P55789 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6906444 1.00 KMT2A (0.86) KMT2AMEN1CRHBPCRHR2MAPT
SCHEMBL6898866 0.93 KMT2A (1.00) KMT2AMEN1CRHBPCRHR2MAPT
SCHEMBL6898863 0.93 KMT2A (1.00) KMT2AMEN1CRHBPCRHR2MAPT
SCHEMBL6785408 0.92 KMT2A (1.00) KMT2AMEN1CRHBPCRHR2MAPT
SCHEMBL6786122 0.92 KMT2A (0.81) KMT2AMEN1CRHBPCRHR2MAPT
SCHEMBL6786118 0.92 KMT2A (0.81) KMT2AMEN1CRHBPCRHR2MAPT
SCHEMBL6779900 0.89 KMT2A (1.00) KMT2AMEN1CRHBPCRHR2MAPT
SCHEMBL6779898 0.89 KMT2A (1.00) KMT2AMEN1CRHBPCRHR2MAPT
SCHEMBL6785294 0.83 MAPT (0.86) KMT2AMEN1CRHBPCRHR2MAPT
SCHEMBL6785292 0.83 MAPT (0.86) KMT2AMEN1CRHBPCRHR2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6727267-B2 COMPOUND FOR USE IN THE TREATMENT OF VIRAL DISEASES TULARIK INC. 2004-04-27 — — US disclosed
US-20020142290-A1 Compound for use in the treatment of viral diseases TULARIK INC. (US) 2002-10-03 — — US disclosed
WO-2001077091-A2 NS5B HCV POLYMERASE INHIBITORS TULARIK INC. (US) 2001-10-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020142290-A1 Compound for use in the treatment of viral diseases POLRMT, RNASE1, POLI KMT2A 2870/4885MEN1 4349/4885CRHBP 1918/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback